Tim Sandle has written an article looking at the impact of Brexit on European pharmaceutical companies.
Here is the introduction:
“Of the different sectors of the British economy affected by the U.K.’s impending exit from the European Union, the pharmaceutical sector is one of the most significant. This relates to both the value of the market and the regulatory impact.
Companies who market pharmaceuticals in the European Union and in the U.K. will need to plan and make decisions in advance of the U.K.’s departure from the European Union in March 2019. Here companies need to decide whether they shift operation to Europe; or maintain a U.K. and European base; or exit the U.K. entirely. These decisions are not helped by the current cloud of political uncertainty and indecisiveness from the government.”
The reference is:
Sandle, T. (2018) Brexit uncertainty for pharmaceutical companies, Pharmig News, Issue 72, pp5-6
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology
